Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6212782 | 0.93 | KCNH2 (0.38) | SLC2A1KCNH2CCR8 | |
| Oxalic Acid SCHEMBL6215855 | 0.93 | SLC2A1 (0.40) | SLC2A1KCNH2CCR8 | |
| SCHEMBL6214723 | 0.90 | KCNH2 (0.36) | SLC2A1KCNH2CCR8 | |
| SCHEMBL6221361 | 0.81 | KCNH2 (0.40) | SLC2A1KCNH2CCR8 | |
| Oxalic Acid SCHEMBL6222732 | 0.81 | SLC2A1 (0.39) | SLC2A1KCNH2 | |
| SCHEMBL6214270 | 0.81 | KCNH2 (0.51) | KCNH2 | |
| Oxalic Acid SCHEMBL7831830 | 0.77 | SLC2A1 (0.39) | SLC2A1KCNH2CCR8 | |
| SCHEMBL5655706 | 0.77 | KCNH2 (0.38) | SLC2A1KCNH2 | |
| Oxalic Acid SCHEMBL6224062 | 0.76 | SLC2A1 (0.38) | SLC2A1KCNH2CCR8 | |
| Trifluoroacetic Acid SCHEMBL5656444 | 0.74 | KCNH2 (0.36) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1127057-B1 | NAPHTHYRIDINE COMPOUNDS AND THIER AZAISOSTERIC ANALOGUES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2005-05-04 | — | — | EP | disclosed |
| US-20030212084-A1 | Naphthrydine compounds and their azaisosteric analogues as antibacterials | HATTON IAN KEITH (GB) | 2003-11-13 | — | — | US | disclosed |
| EP-1127057-A1 | NAPHTHYRIDINE COMPOUNDS AND THIER AZAISOSTERIC ANALOGUES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000021948-A1 | NAPHTHRYDINE COMPOUNDS AND THEIR AZAISOSTERIC ANALOGUES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212084-A1 | Naphthrydine compounds and their azaisosteric analogues as antibacterials | NGLY1, NRDC, ALPI | SLC2A1 4335/4885KCNH2 2232/4885CCR8 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.